Metzger Michael A's Form 4 filing
Syndax Pharmaceuticals IncSNDX · filed Sep 8, 2025
- Accession no.
- 0000950170-25-113659
- Filed
- Sep 8, 2025
- Trade date
- Sep 8, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.58M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Metzger Michael ACIK 0001507220 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2025 | Common Stock | MOption exerciseAcquired | +157,307 | $10.90 | +$1,714,646.3 | 455,968 | Direct | |
| Sep 8, 2025 | Common Stock | SSaleDisposed | −157,307 | $16.41F2 | −$2,581,407.87 | 298,661 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2025 | Common Stock | MOption exerciseAcquired | +157,307 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale prices ranged from $16.21 to $17.06.
Referenced by the price of 1 transaction in Table I.